Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue
Two new patents approved for issue bringing total to 16 granted patents.
Small Pharma Reports Fiscal Third Quarter 2023 Highlights
Positive top-line results from Phase IIa trial of SPL026 in MDD with new trials underway.
Small Pharma reports positive top-line results from Phase IIa trial of SPL026 in Major Depressive Disorder
Primary endpoint met. SPL026 demonstrates rapid and durable response.
First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026
Study will compare the profile of intramuscular versus intravenous SPL026 administration.
Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property
Last patient last visit complete in SPL026 Phase IIa clinical trial, plus new European patent…
First patient dosed in Small Pharma’s Drug Interaction study
Open-label study will assess the interaction between SSRI antidepressants and SPL026.
Small Pharma to support University College London research project on neuroplasticity
Small Pharma will provide its lead candidate SPL026 for the UCL brain-imaging study.
Small Pharma Receives Approval For First-In-Human Phase I Clinical Trial With SPL028
Aims to assess the safety & tolerability of IM and IV administration of SPL028.
Second United States Patent Granted For Small Pharma’s Psychedelics Portfolio
Brings total to twelve granted patents across the Company’s full portfolio.
Small Pharma Reports Fiscal Second Quarter 2023 Highlights
Second quarter 2023 highlights including last patient dosed.